Kingworld Medicines Group Limited Stock

Equities

1110

KYG5268M1006

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:22 2024-05-10 am EDT 5-day change 1st Jan Change
0.58 HKD +5.45% Intraday chart for Kingworld Medicines Group Limited +9.43% -7.94%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 958M 133M 1.04B Sales 2023 1.08B 149M 1.17B Capitalization 356M 49.34M 386M
Net income 2022 22M 3.05M 23.79M Net income 2023 38M 5.26M 41.1M EV / Sales 2022 0.52 x
Net Debt 2022 34.51M 4.78M 37.32M Net Debt 2023 160M 22.2M 173M EV / Sales 2023 0.48 x
P/E ratio 2022
20 x
P/E ratio 2023
8.89 x
Employees 1,002
Yield 2022
2.9%
Yield 2023
5.34%
Free-Float 33.63%
More Fundamentals * Assessed data
Dynamic Chart
Kingworld Medicines Posts 68% Jump in 2023 Profit MT
Kingworld Medicines Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024 CI
Kingworld Medicines Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kingworld Medicine Expects Up to 75% Profit Jump in 2023; Shares Up 6% MT
Kingworld Medicines Group Limited Provides consolidated Earnings Guidance for the Year Ended 31 December 2023 CI
Kingworld Medicines Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kingworld Medicines Subsidiary Buys Shares in Taiko Pharmaceutical MT
Kingworld Medicines Group Expects Up to 40% Rise in H1 Profit MT
Kingworld Medicines Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2023 CI
Kingworld Medicines Group Limited Approves Final Dividend for the Year Ended 31 December 2022 CI
Kingworld Medicines to Invest 832 Million Yen in Taiko Pharmaceutical MT
Kingworld Medicines to Grant 3.5 Million Awarded Shares Under 2019 Scheme MT
Kingworld Medicines Group Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2022, Payable on 30 June 2023 CI
Kingworld Medicines Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
KIngworld Medicines Group Acquires 60% Stake in Innopharm MT
More news
1 day+5.45%
1 week+9.43%
Current month+5.45%
1 month+11.54%
3 months+7.41%
6 months-22.67%
Current year-7.94%
More quotes
1 week
0.53
Extreme 0.53
0.59
1 month
0.50
Extreme 0.5
0.59
Current year
0.49
Extreme 0.485
0.67
1 year
0.49
Extreme 0.485
0.92
3 years
0.37
Extreme 0.365
1.10
5 years
0.37
Extreme 0.365
1.19
10 years
0.37
Extreme 0.365
2.84
More quotes
Managers TitleAgeSince
Chief Investment Officer 42 15-07-31
Comptroller/Controller/Auditor 63 -
Comptroller/Controller/Auditor 64 09-06-24
Members of the board TitleAgeSince
Director/Board Member 56 10-11-04
Founder 61 95-12-31
Founder 66 95-12-31
More insiders
Date Price Change Volume
24-05-10 0.58 +5.45% 1,120,000
24-05-09 0.55 -1.79% 1,016,000
24-05-08 0.56 +5.66% 1,140,000
24-05-07 0.53 -5.36% 1,028,000
24-05-06 0.56 +5.66% 868,000

Delayed Quote Hong Kong S.E., May 10, 2024 at 04:08 am EDT

More quotes
Kingworld Medicines Group Limited is an investment holding company principally engaged in the distribution and sales of pharmaceutical and healthcare products. The Company’s products include cough and phlegm relieving, gastrointestinal, vitamin, orthopedics, cardiovascular, influenza and others. The Company operates through two business segments. The Distribution Sales of Pharmaceutical and Healthcare Products segment is engaged in the distribution and sales of branded imported pharmaceutical and healthcare products primarily in Hong Kong and the People’s Republic of China (PRC). The Manufacturing and Sales of Electrotherapeutic and Physiotherapeutic Devices and General Medical Examination Devices segment is engaged in the manufacture and sales of electrotherapeutic and physiotherapeutic devices, as well as general medical examination devices in the PRC.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW